SMARCB1-deficient tumors show sensitivity to inhibition of the proteasome machinery and autophagy pathways [175], while SMARCA4 mutated lung cancer cells have increased oxygen consumption and enhanced respiratory capacity. Here, SMARCA4 is linked to lung cancer.